Custom Antibody Market worth $901 million in 2029
The report "Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) - Global Forecast to 2029"custom antibody market is expected to reach USD 901 million in 2029 from USD 579 million in 2024, at a CAGR of 9.2% during the forecast period.
Browse 472 market data Tables and 52 Figures spread through 376 Pages and in-depth TOC on "Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology, Infectious, CVD) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/custom-antibody-market-164328301.html
The surge in biomedical and clinical research activities, particularly in academia and research institutions, fuels the demand for custom antibodies. Moreover, the advancements in biotechnology and genetic engineering have significantly improved the development and production of custom antibody, enhancing their specificity and efficacy. The biopharmaceutical industry's growing focus on biologics and biosimilars fuelling the demand for custom antibody.
The antibody development segment accounted for the largest share by service segment in the custom antibody market in 2023.
By service, the custom antibody market is categorized into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development segment is further sub-segmented into antigen preparation, immunization & hybridoma production, and antibody characterization. The antibody development segment accounted for the largest share of the global custom antibody market in 2023. The large share of antibody development is due to the growing trend towards personalized medicine, which requires the creation of antibodies tailored to individual patient profiles, which has boosted the market.
The monoclonal antibodies segment accounted for the largest share by type segment in the custom antibody market in 2023.
By type, the custom antibody market is categorized into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. The monoclonal antibodies segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the high specificity and affinity for their targets, making them highly effective for treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibodies, especially monoclonal antibodies, have the unique ability to specifically target cancer cells without affecting normal cells. This targeted approach minimizes side effects and improves therapeutic efficacy, making antibodies highly valuable in cancer treatment.
The mice segment is expected to grow at a higher rate during the forecast period.
Based on sources, the custom antibody market has been segmented into mice, rabbits, and others. In 2023, the mice segment accounted for the largest share of the custom antibody market and is expected to grow at a higher growth rate during the forecast period of 2024-2029. Mice are relatively inexpensive to purchase and maintain compared to larger animals. Their small size and fast reproduction rates make them cost-effective for large-scale antibody production.
The oncology segment accounted for the largest share of the indication segment in the custom antibody market in 2023.
Based on the indication, the custom antibody market is segmented into oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and other indications. In 2023, the oncology segment accounted for the largest share of the custom antibody market. A significant number of approved monoclonal antibody therapies are for cancer treatment. These therapies, such as immune checkpoint inhibitors, monoclonal antibodies targeting specific antigens on cancer cells, and antibody-drug conjugates (ADCs), have demonstrated remarkable success in treating various types of cancer.
The North American region accounted for the largest share of the custom antibody market in 2023.
The custom antibody market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North America region is witnessing increasing investments and in the field of drug discovery & development, supporting the growth of custom antibody. Moreover, the need for novel targeted therapies has contributed to the growth of the custom antibody market. The substantial investment in research and development within North America fuels the custom antibody market. Government initiatives, private funding, and venture capital investments are directed towards biopharmaceutical research, particularly in areas like cancer, infectious diseases, and autoimmune disorders. These investments facilitate the discovery and development of novel antibodies and enhance the capabilities of custom antibody production.
Key players in the custom antibody market are Thermo Fisher Scientific Inc. (US), GenScript (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Revvity, Inc. (US), Bio-Techne (US), ROCKLAND IMMUNOCHEMICALS, INC. (US), Laboratory Corporation of America Holdings (US), Inotiv (US), Danaher Corporation (US), Sino Biological, Inc. (China), KANEKA CORPORATION (Japan), OriGene Technologies, Inc. (US), Absolute Biotech (US), Biointron Biologics (China), Cell Signaling Technology, Inc. (US), Curia Global, Inc. (US), Mabtech (Sweden), ACROBiosystems (US), Elabscience Bionovation Inc. (US), Creative Diagnostics (US), CUSABIO TECHNOLOGY LLC (US), BioGenes GmbH (Germany), RayBiotech, Inc. (US), Proteintech Group, Inc (US), IMGENEX INDIA Pvt Ltd. (India), Synbio Technologies (US), ProSci Incorporated (US), Creative Biolabs (US).
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian